Hepion Pharmaceuticals, Inc. (CTRVP) intrinsic value & 10-year financials
Hepion Pharmaceuticals, Inc. (CTRVP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -3112.4%
- Free cash flow (FY2025)
- —
CTRVP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.3M | -$0.88 | — | — | -2058.6% |
| FY2024 | — | -$13.2M | -$1.39 | — | — | 213.1% |
| FY2023 | $0 | -$48.9M | -$0.16 | -$40.9M | — | 1098.8% |
| FY2022 | $0 | -$42.2M | -$0.01 | -$35.0M | — | -23444.8% |
| FY2021 | $0 | -$32.7M | -$0.01 | -$31.4M | — | -3405.2% |
| FY2020 | $0 | -$20.4M | -$0.00 | -$16.3M | — | -1392.9% |
| FY2019 | — | -$6.7M | — | -$7.6M | — | -234.4% |
| FY2018 | — | -$9.4M | -$0.00 | — | — | -250.4% |
| FY2017 | — | -$14.9M | -$0.00 | -$19.2M | — | -359.2% |
| FY2016 | — | -$17.0M | -$0.00 | -$16.6M | — | -1290.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Hepion Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Hepion Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -31.1% ROIC.
Over the decade, Hepion Pharmaceuticals, Inc. shows that management has aggressively returned capital to shareholders by retiring 99.9% of outstanding shares.
Benjamin Graham lens
Hepion Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.